Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12614001327673
Ethics application status
Approved
Date submitted
8/12/2014
Date registered
17/12/2014
Date last updated
6/07/2016
Type of registration
Retrospectively registered
Titles & IDs
Public title
Dressing and securement of peripherally inserted central catheters (PICCs) in paediatrics; a pilot, randomised controlled trial
Query!
Scientific title
Randomised controlled trial of tissue adhesive, combined securement and dressing product versus standard care dressings to prevent peripherally inserted central catheter failure in paediatric acute care patients: The CASCADE Junior PICC trial
Query!
Secondary ID [1]
285802
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1164-9991
Query!
Trial acronym
The CASCADE Junior PICC trial
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Central venous access device failure prior to completion of therapy
293695
0
Query!
Condition category
Condition code
Public Health
293997
293997
0
0
Query!
Health service research
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Patients in this study have peripherally inserted central catheters (PICCs) in medical, surgical, anaesthetic and intensive care departments, and only paediatric patients. Consenting parents or legal guardians, and patients (if appropriate) will have their PICCs secured with one of the following randomly assigned dressings and securements:
Arm 1: Tissue Adhesive (TA) is a medical grade 'superglue'
(cyanoacrylate) used mainly to close skin lacerations/wounds as an alternative to sutures and staples. A bordered polyurethane dressingwill also be applied.
Arm 2: Combined securement and dressing product: extra-reinforced borders, with an absorbent layer around the polyurethane claimed to ‘wick’ moisture away from the wound
Arm 3 (Control): Sutureless Stabilisation Device (SSD) have a large adhesive padded footplate with locking clasp made of hard plastic. SSD are used in addition to bordered polyurethane. Bordered polyurethane (BPU) dressings involve a clear
polyurethane with an added external adhesive border of foam or cloth fabric.
The randomly allocated dressing will be applied until completion of therapy, hospital discharge or at 4 weeks. The dressing will be applied at PICC insertion and then changed every 7 days, or on disruption of the dressing integrity.
Query!
Intervention code [1]
290776
0
Prevention
Query!
Intervention code [2]
290829
0
Treatment: Devices
Query!
Comparator / control treatment
Arm 3 (Control): Sutureless Stabilisation Device (SSD) have a large adhesive padded footplate with locking clasp made of hard plastic. SSD are used in addition to bordered polyurethane. Bordered polyurethane (BPU) dressings involve a clear
polyurethane with an added external adhesive border of foam or cloth fabric.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
293778
0
PICC failure or complication: Composite measure of any reason for unplanned PICC removal or complication, prior to the completion of therapy. This includes (i) Central Line-Associated Bloodstream Infection (CLABSI); (ii) local infection of skin or sutures: (iii) dislodgement: (iv) occlusion; (v) CVAD breakage or (vi) venous thrombosis. The primary outcome of device failure is an objective measure, assigned by clinical staff (not research staff or investigators). This is routine clinical practice. Research staff will collect the primary endpoint from the medical records with additional information obtained from the clinical staff/patients if required
Query!
Assessment method [1]
293778
0
Query!
Timepoint [1]
293778
0
At time of PICC removal, hospital discharge or 4 weeks.
Query!
Primary outcome [2]
293779
0
Primary Outcome: Feasibility of a full efficacy trial as established by:
*Eligibility: Percentage of patients screened that are eligible;
*Recruitment: Percentage of eligible patients who agree to enrol;
*Retention and attrition: Percentage of participants who are lost to followup or withdraw from study;
*Protocol adherence: Percentage of participants who receive their
allocated treatment throughout their study participation;
*Missing data: Percentage of data missed during study data collection;
*Parent and healthcare staff satisfaction and acceptability: Using a semistructured survey; and
*Sample size estimates: a reduction in all-case CVAD failure or complication (defined in the secondary outcomes) by at least 5% in the experimental arms, in comparison to standard care.
Query!
Assessment method [2]
293779
0
Query!
Timepoint [2]
293779
0
At time of PICC removal, hospital discharge or 4 weeks
Query!
Secondary outcome [1]
311805
0
Central line-associated bloodstream infection (CLABSI):
A laboratory-confirmed bloodstream infection (LCBI) in a patient who had a central line within the 48 hour period before the development of the BSI, and that is not related to an infection at another site. The CLABSI must meet one of the following criteria of LCBI: Criterion 1: Patient has a recognised pathogen cultured from one or more blood cultures and
Organism cultured from blood is not related to an infection at another
site. OR Criterion 2: Patient has at least one of the following signs or
symptoms: fever (greater than 38 degrees C), chills, or hypotension, and signs and symptoms and positive laboratory results are not related to an infection at another site, and common skin contaminant* is cultured from two or more blood cultures drawn on separate occasions. Examples of common skin contaminants: diphtheroids [Corynebacterium spp.], Bacillus [not B. anthracis] spp., Propionibacterium spp., coagulasenegative staphylococci [including S. epidermidis], viridans group streptococci, Aerococcus spp., Micrococcus spp.
Query!
Assessment method [1]
311805
0
Query!
Timepoint [1]
311805
0
At conclusion of study
Query!
Secondary outcome [2]
311806
0
Local infection of the skin:
Purulent discharge, or redness extending 1cm beyond the site that
prompts clinician to order removal, or commence antimicrobial therapy.
Query!
Assessment method [2]
311806
0
Query!
Timepoint [2]
311806
0
At time of removal, hospital discharge or 4 weeks
Query!
Secondary outcome [3]
311807
0
Dislodgement:
Partial: any post-insertion change in the length of the PICC body from the hub to the PICC tip, as measured by the catheter marking in closest approximation to hub.
Total: PICC body completely leaves the vein, or must be removed because PICC tip is no longer in the superior vena cava (diagnosed by XRay/leakage from site on injection/clinician diagnosis)
Query!
Assessment method [3]
311807
0
Query!
Timepoint [3]
311807
0
At time of removal, hospital discharge or 4 weeks
Query!
Secondary outcome [4]
311808
0
Occlusion:
>/=1 lumen unable to be flushed/aspirated, diagnosed by treating
clinician
Query!
Assessment method [4]
311808
0
Query!
Timepoint [4]
311808
0
At time of removal, hospital discharge or 4 weeks.
Query!
Secondary outcome [5]
311809
0
PICC breakage:
Visible split in PICC material diagnosed by treating clinician
Query!
Assessment method [5]
311809
0
Query!
Timepoint [5]
311809
0
At time of removal, hospital discharge of 4 weeks.
Query!
Secondary outcome [6]
311810
0
Dressing/securement failure:
Early replacement before seven days for loose, soiled or missing
dressings
Query!
Assessment method [6]
311810
0
Query!
Timepoint [6]
311810
0
At seven days after dressing application
Query!
Secondary outcome [7]
311811
0
PICC dwell time, and dressing dwell time:
Time in hours from insertion/application until removal
Query!
Assessment method [7]
311811
0
Query!
Timepoint [7]
311811
0
At time of PICC removal
Query!
Secondary outcome [8]
311812
0
Parent and staff satisfaction and acceptability ranked on a 10-point
scale
Query!
Assessment method [8]
311812
0
Query!
Timepoint [8]
311812
0
At device removal, at hospital discharge or 4 weeks
Query!
Secondary outcome [9]
317162
0
Venous thrombosis: Development of thrombosed vessel (partial or complete) at the CVAD site diagnosed radiologically as requested by the treating clinician in a symptomatic patient
Query!
Assessment method [9]
317162
0
Query!
Timepoint [9]
317162
0
Time of removal, hospital discharge or 4 weeks
Query!
Secondary outcome [10]
317163
0
Cost effectiveness: Estimates of direct product costs, healthcare resource utilisation (including additional equipment, staff time) and failure-associated resource usage using previously established cost estimates
Query!
Assessment method [10]
317163
0
Query!
Timepoint [10]
317163
0
At study completion
Query!
Secondary outcome [11]
317164
0
Safety: Skin complications including skin rash, skin tears, blisters, pruritis, local or systemic allergic reaction
Query!
Assessment method [11]
317164
0
Query!
Timepoint [11]
317164
0
Time of removal, hospital discharge or 4 weeks
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
*Patient requires the insertion of a PICC for >24 hours;
*Will remain in admitted to the RCH/LCCH for >24 hours; and
*Parent or legal guardian, and child if developmentally appropriate, givesinformed consent.
Query!
Minimum age
No limit
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
*Non-tunnelled, tunnelled, dialysis, or implanted CVADs or
pulmonary artery catheters;
*Current bloodstream infection;
*PICC to be inserted through diseased, burned or scarred skin;
*Allergy to study product; and
*Previous study enrolment in this admission to hospital.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The research nurse (RN) will screen patients daily (screening log kept), gain informed consent, and perform randomisation. The RN will have the study products in pre-packs and liaise closely with the ordering and inserting surgeon. All elligible patients (or
their representative) will be approached for written informed consent by the RN or inserter. If this is given, the staff member use a centralised web-based randomisation service. Allocation is fully concealed until the patient is randomised.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated. Randomisation will be in a 1:1:1 ratio between the three study groups. Permuted blocks in randomly varied sizes will be used.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
All randomised patients will be analysed by intention to treat, regardless of treatment received. The patient is the unit of measurement with one PICC per patient.
Feasibility outcomes will be described using descriptive statistics
including mean, median, range, IQR, counts and percentages.
Comparability of groups at baseline will be assessed using clinical parameters. Relative incidence rates of PICC and dressing failure per 100 devices and per 1,000 device days with 95% confidence intervals (CIs) will summarise the impact of each dressing, and to test difference between groups. Kaplan-Meier survival curves (with log rank Mantel-Cox test) will compare PICC failure over time. Secondary endpoints including dwell-time, costs, dislodgement, occlusion, breakage, patient/staff satisfaction scores and adverse events will be compared between groups using parametric/nonparametric
techniques as appropriate. Data will be exported into PASW 21.0 (SPSS Inc, Chicago, IL). Prior to analysis, data
cleaning of outlying figures, missing, and implausible data will be undertaken, and a random 5% sample of source data rechecked. All attempts will be made to collect the primary endpoint. Missing data will be modelled for best- and worst-case outcomes to assess for effect on overall results. A per-protocol analysis will assess the effect of protocol violations. P values of <0.05 will be considered significant.
Sample size and study power: This is a pilot study to gain information to prepare for an efficacy trial. Thirty participants per study arm will be recruited - totaling 90 participants.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/06/2014
Query!
Actual
2/06/2014
Query!
Date of last participant enrolment
Anticipated
4/10/2015
Query!
Actual
24/08/2015
Query!
Date of last data collection
Anticipated
Query!
Actual
14/09/2015
Query!
Sample size
Target
90
Query!
Accrual to date
Query!
Final
106
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
3238
0
Royal Children's Hospital - Herston
Query!
Recruitment hospital [2]
3266
0
Lady Cilento Children's Hospital - South Brisbane
Query!
Funding & Sponsors
Funding source category [1]
290365
0
University
Query!
Name [1]
290365
0
Griffith University
Query!
Address [1]
290365
0
Nathan Campus,
170 Kessels Road,
Nathan, QLD 4111
Query!
Country [1]
290365
0
Australia
Query!
Funding source category [2]
290366
0
Commercial sector/Industry
Query!
Name [2]
290366
0
Centurion Medical Products
Query!
Address [2]
290366
0
100 Centurion Way
Williamstown, MI 48895
United States
Query!
Country [2]
290366
0
United States of America
Query!
Primary sponsor type
University
Query!
Name
Griffith University
Query!
Address
Nathan Campus,
170 Kessels Road,
Nathan, QLD 4111
Query!
Country
Australia
Query!
Secondary sponsor category [1]
289088
0
None
Query!
Name [1]
289088
0
Query!
Address [1]
289088
0
Query!
Country [1]
289088
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
292068
0
Children's Health Services, Queensland
Query!
Ethics committee address [1]
292068
0
Royal Children's Hospital
Herston Road
Herston, QLD 4029
Query!
Ethics committee country [1]
292068
0
Australia
Query!
Date submitted for ethics approval [1]
292068
0
Query!
Approval date [1]
292068
0
14/11/2013
Query!
Ethics approval number [1]
292068
0
HREC/13/QRCH/181
Query!
Ethics committee name [2]
292069
0
Griffith University
Query!
Ethics committee address [2]
292069
0
Nathan Campus,
170 Kessels Rd
Nathan, QLD, 4111
Query!
Ethics committee country [2]
292069
0
Australia
Query!
Date submitted for ethics approval [2]
292069
0
Query!
Approval date [2]
292069
0
20/02/2014
Query!
Ethics approval number [2]
292069
0
NRS/10/14/HREC
Query!
Summary
Brief summary
Children admitted to an acute care facility frequently require the insertion of a peripherally inserted central catheter (PICC) for the administration of medication and fluids. These PICCs are associated with a high rate of failure, including PICC-related bloodstream infection (BSI). In order to prevent failure, dressings, such as bordered polyurethane (BPU) and sutureless securement devices (SSD), are used to protect the PICC insertion site from contamination. Additional securement devices, such as sutures, are used to reduce movement of the
catheter.
New products, including tissue adhesive (TA), and combined securement and dressing products (CSD), are available to clinicians to provide securement and dressings for PICC. It is
not known whether these new products are effective at reducing PICC failure and complication, in comparison to standard care (BPU and SSD). The primary aim of this research is to evaluate the feasibility of launching a full-scale efficacy trial, using pre-defined feasibility criteria for recruitment,
retention and protocol fidelity. The secondary aim is to compare the effectiveness of dressings and securement products on PICC failure and complication due to infection, occlusion, dislodgement, thrombosis, or breakage, for children with PICC in acute care.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
53334
0
Ms Amanda Ullman
Query!
Address
53334
0
NHMRC Centre for Research Excellence in Nursing, Griffith University, 170 Kessels Rd, Nathan, QLD 4111
Query!
Country
53334
0
Australia
Query!
Phone
53334
0
+61 7 3735 7854
Query!
Fax
53334
0
Query!
Email
53334
0
[email protected]
Query!
Contact person for public queries
Name
53335
0
Ms Amanda Ullman
Query!
Address
53335
0
NHMRC Centre for Research Excellence in Nursing, Griffith University, 170 Kessels Rd, Nathan, QLD 4111
Query!
Country
53335
0
Australia
Query!
Phone
53335
0
+61 7 3735 7854
Query!
Fax
53335
0
Query!
Email
53335
0
[email protected]
Query!
Contact person for scientific queries
Name
53336
0
Ms Amanda Ullman
Query!
Address
53336
0
NHMRC Centre for Research Excellence in Nursing, Griffith University, 170 Kessels Rd, Nathan, QLD 4111
Query!
Country
53336
0
Australia
Query!
Phone
53336
0
+61 7 3735 7854
Query!
Fax
53336
0
Query!
Email
53336
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
A Pilot Randomized Controlled Trial of Novel Dressing and Securement Techniques in 101 Pediatric Patients.
2017
https://dx.doi.org/10.1016/j.jvir.2017.07.012
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF